叶酸联合阿托伐他汀对轻度认知功能障碍的疗效

发布时间：2018-05-24 14:37

本文选题：轻度认知功能障碍 + 老年痴呆　；参考：《安徽医科大学》2012年硕士论文

【摘要】：目的随着年龄的增长老年人常常因精神和体力方面能力下降影响其生活质量。精神方面最显著的功能变化是认知功能损害，这在老化过程中非常常见。但是许多老年人其认知功能损害的程度比同龄老年人严重的多。轻度认知功能障碍（MCI）被认为是介于正常老化与老年痴呆之间的过度阶段。当今许多国家步入老龄化，MCI的流行率和发病率随之增加。寻找改善MCI症状和延缓其发展的方法已经成为老年痴呆防治的重中之重。本研究将对轻度认知功能损害的治疗进行深入研究，探讨大剂量叶酸联合阿托伐他汀在轻度认知功能损害患者中的干预作用，积极寻找一种对轻度认知功能损害患者的有效预防和治疗措施. 方法采用前瞻性的研究方法。收集门诊及住院的患者，予以安慰剂服用两周后，，抽取清晨空腹血，测同型半胱氨酸（Hcy），血脂及肝肾功能。再通过简易智能状态量表(MMSE)得分将纳入的研究对象分为正常对照A组和MCI组。再根据是否给予叶酸联合阿托伐他汀药物干预治疗随机分为MCI未治疗B组和MCI治疗C组。予以药物干预治疗半年，药物干预周期结束后再次复测血浆同型半胱氨酸、血脂、肝肾功能，及进行MMSE量表评定，并进行治疗前后及两组间对比。采用MMSE评分量表的措施，进一步探讨叶酸联合阿托伐他汀对MCI患者认知功能的改善情况。结果周期前后A组Hcy、TC及MMSE值均无明显差异，统计学无显著性差异（P＞0.05）；B组MMSE值较之前有所下降，其差异均有显著性意义（P＜0.05），虽Hcy、TC水平有所上升，但无显著性统计学意义；C组MMSE值较之前稍下降，但无显著性统计学意义（P＞0.05），并且Hcy、TC水平也较之前显著降低，其差异有显著统计学意义（P＜0.05）。结论两组MCI患者血浆相较正常对照组Hcy及血脂存在着一定的代谢紊乱。认知功能损害的进展速率相较正常对照组快，两组MCI患者之间相互比较得出叶酸联合阿托伐他汀对MCI患者的认知功能的改善有一定作用，是一种有效的治疗方法。
[Abstract]:Objective with age, the elderly often suffer from mental and physical decline in their quality of life. The most significant mental functional change is cognitive impairment, which is common during aging. But many older people have more severe cognitive impairment than their peers. Mild cognitive impairment (MCI) is thought to be a transitional stage between normal aging and Alzheimer's disease. The prevalence and incidence of MCI are increasing in many countries. Finding ways to improve the symptoms and delay the development of MCI has become a top priority in the prevention and treatment of Alzheimer's disease. In this study, the treatment of mild cognitive impairment was studied, and the intervention effect of high dose folic acid combined with Atto vastatin in patients with mild cognitive impairment was discussed. Actively looking for an effective prevention and treatment for patients with mild cognitive impairment. Methods A prospective study was used. After two weeks of placebo administration, fasting blood samples were collected from outpatients and inpatients. The levels of homocysteine, serum lipids, liver and kidney function were measured. The subjects included in the study were divided into normal control group A and MCI group. According to whether folic acid and Atto vastatin were given, the patients were randomly divided into two groups: group B without MCI and group C treated with MCI. The plasma homocysteine, blood lipid, liver and kidney function, and MMSE scale were measured again after the end of the drug intervention period, and the comparison was made between the two groups before and after the treatment. To further explore the improvement of cognitive function of MCI patients with folic acid combined with Atto vastatin by using MMSE scoring scale. Results there was no significant difference in TC and MMSE between group A and group A before and after the cycle. There was no significant difference in MMSE between group A and group B (P > 0.05), and the difference was significant (P < 0.05), although the level of TC in group A was higher than that in group B (P > 0.05). But there was no significant statistical significance in group C (P > 0.05), but there was no significant difference (P > 0.05), and the level of TC in group C was significantly lower than that in group C (P < 0.05). Conclusion compared with the normal control group, the plasma levels of Hcy and blood lipid in the two groups of MCI patients have some metabolic disorders. The development rate of cognitive impairment was faster than that of normal control group. The results showed that folic acid combined with Atto vastatin could improve the cognitive function of MCI patients and was an effective treatment method.
【学位授予单位】：安徽医科大学
【学位级别】：硕士
【学位授予年份】：2012
【分类号】：R749.16

【参考文献】